Literature DB >> 7675372

Body fat distribution in women with polycystic ovary syndrome.

T Douchi1, H Ijuin, S Nakamura, T Oki, S Yamamoto, Y Nagata.   

Abstract

OBJECTIVE: To investigate body fat distribution in women with polycystic ovary syndrome (PCOS).
METHODS: Body weight, body mass index (BMI), and six indices of body fat measured by dual-energy x-ray absorptiometry were compared in 40 women with PCOS and 97 age-matched controls. The possible correlations between the body fat characteristics and serum androgen levels were evaluated in the 40 PCOS women. Body fat distribution was classified into upper- (N = 24) and lower-half body type (N = 16), and androgen levels and the incidence of hirsutism were compared in the two types.
RESULTS: The BMI, body fat ratio, upper-half body fat ratio, and upper-half/lower-half body fat ratio were significantly higher in PCOS women than in controls. After adjustment for age, height, and body weight, the upper-half/lower-half body fat ratio was still significant (P < .001). The PCOS subjects exhibited a significant positive correlation between the upper-half/lower-half body fat ratio and dehydroepiandrosterone-sulfate (DHEA-S) levels (r = 0.607, P < .01) as well as testosterone levels (r = 0.585, P < .05). Dehydroepiandrosterone-sulfate and testosterone levels were significantly higher in those with the upper-half body type than in those with the lower-half body type (P < .001). After adjustment for confounding variables, only DHEA-S was still significantly higher in this body type (P < .05).
CONCLUSION: Serum DHEA-S levels seem to be associated with upper-half body fat distribution in women with PCOS, irrespective of body weight.

Entities:  

Mesh:

Year:  1995        PMID: 7675372     DOI: 10.1016/0029-7844(95)00250-u

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome--is there a link?

Authors:  J D Wilson; R J Dunham; A H Balen
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Obesity and Polycystic Ovary Syndrome.

Authors:  Susan Sam
Journal:  Obes Manag       Date:  2007-04

Review 3.  Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology.

Authors:  Z E Hopkinson; N Sattar; R Fleming; I A Greer
Journal:  BMJ       Date:  1998-08-01

4.  Fat distribution patterns in young amenorrheic females.

Authors:  S Kirchengast; J Huber
Journal:  Hum Nat       Date:  2001-06

5.  Relationship of androgens to body composition, energy and substrate metabolism and aerobic capacity in healthy, young women.

Authors:  Jennifer L Keller; Peter R Casson; Michael J Toth
Journal:  Steroids       Date:  2011-06-25       Impact factor: 2.668

6.  Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.

Authors:  Dorte Glintborg; Hanne Mumm; Magda Lambaa Altinok; Bjørn Richelsen; Jens Meldgaard Bruun; Marianne Andersen
Journal:  J Endocrinol Invest       Date:  2014-06-07       Impact factor: 4.256

7.  Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome.

Authors:  C M Bruns; S T Baum; R J Colman; D A Dumesic; J R Eisner; M D Jensen; L D Whigham; D H Abbott
Journal:  Int J Obes (Lond)       Date:  2007-05-01       Impact factor: 5.095

8.  Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.

Authors:  E Faloia; P Canibus; C Gatti; F Frezza; M Santangelo; G G M Garrapa; M Boscaro
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

9.  Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome.

Authors:  D Glintborg; A P Hermann; L M Rasmussen; M Andersen
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

10.  Pharmacological treatment of obesity in patients with polycystic ovary syndrome.

Authors:  Hassan Kahal; Stephen L Atkin; Thozhukat Sathyapalan
Journal:  J Obes       Date:  2010-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.